"Lymphoma, B-Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.
Descriptor ID |
D016393
|
MeSH Number(s) |
C04.557.386.480.150 C15.604.515.569.480.150 C20.683.515.761.480.150
|
Concept/Terms |
Lymphoma, B-Cell- Lymphoma, B-Cell
- Lymphoma, B Cell
- B-Cell Lymphoma
- B Cell Lymphoma
- B-Cell Lymphomas
- Lymphomas, B-Cell
|
Below are MeSH descriptors whose meaning is more general than "Lymphoma, B-Cell".
Below are MeSH descriptors whose meaning is more specific than "Lymphoma, B-Cell".
This graph shows the total number of publications written about "Lymphoma, B-Cell" by people in this website by year, and whether "Lymphoma, B-Cell" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 2 | 1 | 3 |
1995 | 0 | 1 | 1 |
1996 | 7 | 0 | 7 |
1997 | 3 | 2 | 5 |
1998 | 9 | 3 | 12 |
1999 | 8 | 2 | 10 |
2000 | 7 | 6 | 13 |
2001 | 13 | 1 | 14 |
2002 | 12 | 6 | 18 |
2003 | 9 | 5 | 14 |
2004 | 10 | 3 | 13 |
2005 | 5 | 6 | 11 |
2006 | 18 | 9 | 27 |
2007 | 21 | 4 | 25 |
2008 | 7 | 0 | 7 |
2009 | 4 | 3 | 7 |
2010 | 6 | 5 | 11 |
2011 | 13 | 1 | 14 |
2012 | 10 | 2 | 12 |
2013 | 15 | 3 | 18 |
2014 | 14 | 0 | 14 |
2015 | 19 | 1 | 20 |
2016 | 8 | 1 | 9 |
2017 | 12 | 1 | 13 |
2018 | 11 | 0 | 11 |
2019 | 10 | 1 | 11 |
2020 | 16 | 0 | 16 |
2021 | 19 | 3 | 22 |
2022 | 13 | 0 | 13 |
2023 | 25 | 0 | 25 |
2024 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lymphoma, B-Cell" by people in Profiles.
-
Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia. Am J Hematol. 2024 Apr; 99(4):586-595.
-
Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat Med. 2024 Feb; 30(2):338-341.
-
Optical genomic mapping is a helpful tool for detecting CCND1 rearrangements in CD5-negative small B-cell lymphoma: Two cases of leukemic non-nodal mantle cell lymphoma. Hum Pathol. 2024 Feb; 144:71-76.
-
Predictive and prognostic molecular biomarkers in lymphomas. Pathology. 2024 Mar; 56(2):239-258.
-
Ex Vivo Expanded Cord Blood Natural Killer Cells Combined with Rituximab and High-Dose Chemotherapy and Autologous Stem Cell Transplantation for B Cell Non-Hodgkin Lymphoma. Transplant Cell Ther. 2024 Feb; 30(2):203.e1-203.e9.
-
Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL. Blood Adv. 2023 11 28; 7(22):6990-7005.
-
Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas. J Immunother Cancer. 2023 11 24; 11(11).
-
Recognizing a Mediastinal Mass: A Case of Primary Mediastinal Large B-Cell Lymphoma With Pruritus in a 23-Year-Old Adult Male Sailor. Mil Med. 2023 11 03; 188(11-12):3687-3691.
-
The synergy of the XPO1 inhibitors combined with the BET inhibitor INCB057643 in high-grade B-cell lymphoma via downregulation of MYC expression. Sci Rep. 2023 10 29; 13(1):18554.
-
Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Patients with Relapsed or Refractory CD20+ B Cell Lymphoma. Transplant Cell Ther. 2024 Feb; 30(2):241.e1-241.e8.